PharmassetX Inc., a late-preclinical stage pharmaceutical development company, today announced that the US Patent and Trademark Office has acknowledged receipt of the Company’s patent application entitled “CRYSTALLINE FORM OF EPIGALLOCATECHIN-3-GALLATE.” PharmassetX is developing the novel form of epigallocatechin gallate (EGCG) as a prescription drug for the treatment of inflammatory bowel disease (IBD).
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
